Immupharma took the stairs #bearishIMM matches the adage, "Markets take the stairs up and the elevator down".
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.01 GBP
−2.48 M GBP
0.00 GBP
430.06 M
About IMMUPHARMA PLC
Sector
Industry
CEO
Timothy Paul McCarthy
Website
Headquarters
London
Founded
2000
ISIN
GB0033711010
FIGI
BBG00MJH1JS0
ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. It is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm's portfolio consists of four novel peptide therapy areas: autoimmunity, metabolism, cancer and anti-infectives. Its drug Lupuzor, is a potential treatment for the autoimmune chronic inflammatory disease lupus. The company was founded by Richard Warr and Dimitri F. Dimitriou in 1999 and is headquartered in London, the United Kingdom.
Related stocks
Immupharma - Risen from the dead or dad cat bounce?All signs look to a dead cat bounce. Obviosuly everyone knows this has been trending down for almost 2 years.
This has no consolidation under the 32p resistance, a weekly close under the previous 19p support is not a good look.
Very good news was fomo'd into. Next news should be a while, thi
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange IMMUPHARMA PLC stocks are traded under the ticker IMML.
IMML reached its all-time high on Nov 29, 2019 with the price of 22.28 GBX, and its all-time low was 1.00 GBX and was reached on Dec 10, 2024. View more price dynamics on IMML chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track IMMUPHARMA PLC financials in yearly and quarterly reports right on TradingView.
IMMUPHARMA PLC is going to release the next earnings report on Sep 25, 2025. Keep track of upcoming events with our Earnings Calendar.
IMML net income for the last half-year is −2.10 M GBP, while the previous report showed −387.85 K GBP of net income which accounts for −440.32% change. Track more IMMUPHARMA PLC financial stats to get the full picture.
No, IMML doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMML shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUPHARMA PLC stock right from TradingView charts — choose your broker and connect to your account.